

### **Amendments to Claims:**

---

1. (currently amended) A method for controlling excessive proliferation or migration of smooth muscle cells comprising treating said smooth muscle cells with an effective amount of an antibody antagonist of a native ErbB4 receptor of SEQ ID NO.: 2.

2. (original) The method of claim 1 wherein the control is prevention of excessive proliferation or migration of smooth muscle cells.

3. (original) The method of claim 1 wherein the control is inhibition of excessive proliferation or migration of smooth muscle cells.

4. (canceled)

5. (original) The method of claim 1 wherein said smooth muscle cells are pyloric smooth muscle cells.

6. (original) The method of claim 1 wherein said smooth muscle cells are urinary bladder smooth muscle cells.

7. (original) The method of claim 1 wherein said smooth muscle cells are those of an airway passage.

8. (original) The method of claim 1 wherein said excessive proliferation or migration of smooth muscle cells results in stenosis.

9. (original) The method of claim 1 wherein said smooth muscle cells are vascular smooth muscle cells.

10. (original) The method of claim 9 wherein said vascular smooth muscle cells are human.

11. (original) The method of claim 9 wherein said vascular smooth muscle cells are human aortic smooth muscle cells.

12. (original) The method of claim 9 wherein said excessive proliferation or migration of smooth muscle cells results in vascular stenosis.

13. (original) The method of claim 12 wherein said vascular stenosis is further characterized by excessive proliferation or migration of endothelial cells.

14. (original) The method of claim 13 wherein said stenosis is restenosis.

15-22 (canceled)

23. (currently amended) The method of claim 22 1 wherein said antibody is a neutralizing antibody against a native ErbB4 receptor of SEQ ID NO.: 2.

24. (original) The method of claim 23 wherein said antibody is a chimeric, humanized or human antibody.

25. (original) The method of claim 23 wherein said antibody is glycosylated.

*ack*  
26. (original) The method of claim 23 wherein said antibody binds essentially the same epitope as an antibody produced by a hybridoma selected from the group consisting of HER4.10H1.1A1 (ATCC Accession Number PTA-2828), HER4.1C6.A11 (ATCC Accession Number PTA-2829), HER4.3B9.2C9 (ATCC Accession Number PTA-2826), HER4.1A6.5B3 (ATCC Accession Number PTA-2827) and HER4.8B1.2H2 (ATCC Accession Number PTA-2825).

27. (original) The method of claim 23 wherein said antibody has complementarity determining region (CDR) residues from an antibody produced by a hybridoma selected from the group consisting of HER4.10H1.1A1 (ATCC Accession Number PTA-2828), HER4.1C6.A11 (ATCC Accession Number PTA-2829),

HER4.3B9.2C9 (ATCC Accession Number PTA-2826), HER4.1A6.5B3 (ATCC Accession Number PTA-2827) and HER4.8B1.2H2 (ATCC Accession Number PTA-2825).

28. (currently amended) A method for treating stenosis in a mammalian patient comprising administering to said patient an effective amount of an antibody antagonist of a native mammalian ErbB4 receptor of SEQ ID NO.: 2.

29. (original) The method of claim 28 wherein said patient is human.

30. (original) The method of claim 29 wherein said stenosis is vascular stenosis.

31. (original) The method of claim 30 wherein said vascular stenosis is restenosis.

AK  
32-36 (canceled)

37. (currently amended) The method of claim ~~36~~ 28 wherein said antibody is a neutralizing antibody against a native human ErbB4 receptor of SEQ ID NO.: 2.

38. (currently amended) The method of claim ~~36~~ 28 wherein said antibody binds essentially the same epitope as an antibody produced by a hybridoma selected from the group consisting of HER4.10H1.1A1 (ATCC Accession Number PTA-2828), HER4.1C6.A11 (ATCC Accession Number PTA-2829), HER4.3B9.2C9 (ATCC Accession Number PTA-2826), HER4.1A6.5B3 (ATCC Accession Number PTA-2827) and HER4.8B1.2H2 (ATCC Accession Number PTA-2825).

39. (currently amended) The method of claim ~~36~~ 28 wherein said antibody has complementarity determining region (CDR) residues from an antibody produced by a hybridoma selected from the group consisting of HER4.10H1.1A1 (ATCC Accession Number PTA-2828), HER4.1C6.A11 (ATCC Accession Number PTA-2829),

HER4.3B9.2C9 (ATCC Accession Number PTA-2826), HER4.1A6.5B3 (ATCC Accession Number PTA-2827) and HER4.8B1.2H2 (ATCC Accession Number PTA-2825).

40. (currently amended) The method of claim 28 wherein said antibody antagonist is administered as an injection or infusion.

41. (original) The method of claim 28 wherein said treatment additionally reduces hypertension associated with said stenosis.

42. (original) The method of claim 28 wherein said treatment is prevention.

43. (original) The method of claim 28 wherein said stenosis is pyloric stenosis.

A4  
44. (original) The method of claim 28 wherein said stenosis is thickening of the urinary bladder wall.

45. (original) The method of claim 28 wherein said stenosis is part of an obstructive airway disease.

46-84 (canceled)

---